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Gene promoterMultidrug resistance (MDR), one of the main reasons for diminishing efﬁcacy of prolonged chemo-
therapy, is frequently caused by the elevated expression of the ABCB1/MDR1 gene encoding PGP
(P-glycoprotein). EAPP (E2F Associated PhosphoProtein) is a frequently overexpressed protein in
human tumor cells. It inhibits apoptosis in a p21-dependent manner. We show here that EAPP stim-
ulates the MDR1 promoter resulting in higher PGP levels. Independently of EAPP, E2F1 also increases
the activity of the MDR1 promoter. Co-expression of pRb inhibits E2F1-, but not EAPP-dependent
promoter activation. The upregulation of PGP might contribute to the survival of tumor cells during
chemotherapy and worsen the prognosis for the patient.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction expression of these proteins is inﬂuenced by p53 in a conditionalThe success of prolonged chemotherapy is often severely
impaired by resistance to anti-cancer drugs. Two general classes
of resistance exist: those that diminish delivery of the drugs to
tumor cells, and those that develop in the cancer cell itself due
to genetic and epigenetic modiﬁcations that reduce drug sensitiv-
ity. Poor absorption, increased metabolism or excretion and re-
duced diffusion from the blood into the tumor can be the reasons
for impaired drug delivery [1,2]. The emergence of drug resistant
cells can be easily studied by in vitro selection of cultured cells
resistant to cytotoxic agents. These cells usually exhibit resistance
to a variety of anticancer agents. Several different forms of such a
multidrug resistance (MDR) have been identiﬁed. The most com-
mon forms are the P-glycoprotein (PGP) and the ‘‘multidrug resis-
tance associated protein’’ (MRP) mediated MDR. Both kinds of
proteins are members of a large family of ATP-dependent mem-
brane proteins called ABC (ATP-binding cassette) transporters
(for reviews see [3]). The principal function of PGP and the MRPs
appears to be protection of the cell from xenobiotics. PGP is also
essential for the maintenance of the blood–brain barrier [4]. Themanner, depending on the cell type and the status of p53 (re-
viewed in [5]). There are indications, although not undisputed, that
wild-type p53 represses and mutant p53 stimulates the expression
of the ABCB1 (MDR1/PGP) [6,7] and the ABCC1 (MRP1) gene [8].
Transcriptional regulation of the human MDR1 gene seems to be
rather complex and inﬂuenced by a variety of promoter binding
factors but also by epigenetic mechanisms (for reviews see [9,10]).
E2F is a family of transcription factors that integrate cell-cycle
progression with transcription through cyclical interactions with
important regulators, such as the retinoblastoma-tumor-suppres-
sor-gene product (pRB), cyclins and cyclin dependent kinases. E2F
regulates genes, the products of which are essential for progression
through the mammalian cell cycle. On the other hand, overexpres-
sion of E2F1 can induce apoptosis that is p53-dependent, but also
p53-independent by direct activation of genes coding for proteins
such as p73, Apaf-1 and caspases. The discovery that the expression
of p14ARF, a tumor suppressor that prevents p53 degradation, and
the expression of ATM and Chk2, kinases involved in the DNA dam-
age response that phosphorylate (and stabilize) p53, is regulated by
E2F provided a link between the pRB and p53 networks (reviewed in
[11]). We have identiﬁed and characterized a protein that interacts
with the activating E2F members and stimulates E2F-dependent
transcription. Due to its strong phosphorylation we named it EAPP
(E2F Associated PhosphoProtein) [12]. EAPP is enriched in the nu-
cleus, but can also be found in the cytoplasm. Analyses of human tu-
mor cell lines revealed that almost all express higher levels of EAPP
than comparable untransformed cells [13]. EAPP is an essential
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levels increase upon DNA damage and this protects cells from apop-
tosis in a p21-dependent manner. It turned out that EAPP binds to
the p21 promoter via GC boxes in the vicinity of the TATA box and
stimulates its activity [14]. Besides p21, the expression of themono-
amine oxidase B gene is also regulated by EAPP [15].
Moreover, we found that EAPP selectively interacts with
P-Thr68-Chk2 (checkpoint kinase 2) but not with unphosphory-
lated Chk2. This interaction results in enhanced dephosphorylation
and thus inactivation of Chk2, indicating that EAPP plays a role in
checkpoint recovery after successful damage repair [16].
We show here that independently of each other both, EAPP and
E2F1 stimulate the promoter of the MDR1 gene, resulting in in-
creased expression and higher levels of PGP. This might contribute
to the development of a multidrug resistance phenotype.Fig. 1. EAPP overexpression increases the G1 fraction of T98G and SAOS cells. Two
series of cells were transfected with an HA-EAPP expressing or a control vector. 24 h
later one series was treated for 16 h with nocodazole. Subsequently cells were
harvested and analyzed for cell-cycle distribution.2. Materials and methods
2.1. Plasmids, reporter constructs, and reagents
pCIneo-HA-EAPP, pCIneo-MCS, pGAL-Luc, pCIneo-HA-E2F1 [12],
pCIneo-HA-pRb(Dcdk) [17], Mdr1-Luc and Mdr1(Y-Box mutated)-
Luc [18] have been described.
Etoposide, Nocodazole, MMS and Colchicine were purchased
from Sigma–Aldrich and solved as recommended.
2.2. Cell culture and transfection
T98G and SAOS cells were purchased from ATCC and cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing 10% fetal
calf serum (FCS).
Cells were transfected for 16 h using PerFectin (Genlantis).
Medium was changed and cells grown for additional 24–48 h. As
a control and to achieve equal amounts of DNA pCIneo-MCS was
used.
2.3. Western blot analysis
Whole cell extracts were prepared by using a lysis buffer
(20 mM Tris, pH 8, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40). The
separation was performed by SDS–polyacrylamide gel electropho-
resis. Proteins were then transferred onto nitrocellulose and
probed with indicated antibodies, followed by enhanced chemilu-
minescence and detection with X-ray ﬁlms (Fuji).
The a-EAPP antibody has been described [14]. The a-Mdr1 (H-
241) was purchased from Santa Cruz Biotechnology, anti-HA
(16B12) fromAbcam,anda-b-Actin (AC-74) fromSigma. ImageQuant
(Molecular Dynamics) was used for quantiﬁcation of the signals.
2.4. Luciferase reporter assay
Reporter assays were carried out as previously described [12]
with a wild type and Y-Box mutated Mdr1-promoter-luciferase re-
porter construct. b-Galactosidase activity was assayed in parallel as
a control for the transfection efﬁciency.
2.5. Cell cycle analysis
The cell cycle distribution was measured with DAPI (Merck).
Cells were trypsinized, washed once with PBS and around
5  105 cells were taken. For the staining cells were ﬁxed in 85%
ethanol and incubated at least 30 min on ice. The DAPI concentra-
tion was 2 ng/ml and ﬁxed cells were incubated for 20 min in the
dark at 4 C. A PARTEC PasIII was used to measure the DAPI concen-
tration in the cells.3. Results
3.1. EAPP stimulates the expression of MDR1 at the level of
transcription
The treatment of proliferating cells with drugs like nocodazole
that interfere with the assembly of the mitotic spindle results in
the activation of checkpoint proteins. The following abrupt halt
of cell cycle progression can be readily observed by analysis of
the cell cycle proﬁle of the respective cells. The cell cycle proﬁle
of EAPP-overexpressing cells differed radically from control cells
when both were treated with nocodazole (Fig. 1 and [14]).
Whereas in control cells drug treatment arrested cells in G2/M,
EAPP overexpression led to a dramatic increase of the G1 fraction.
Two mechanisms offered a plausible explanation for this observa-
tion. (1) EAPP induced a G1 arrest irrespective of the drug treat-
ment, or (2) EAPP stimulated the expression and/or activity of
ABC proteins that pumped the xenobiotic drugs out of the cell thus
allowing continued proliferation. We followed both routes and in
the end it turned out that the EAPP-stimulated upregulation of
p21 caused the G1 arrest [14]. Nevertheless, we also found an
inﬂuence of EAPP on the expression of MDR1/PGP, one of the
ABC transporters. Fig. 2A shows the increase of MDR1 levels upon
overexpression of EAPP. To ﬁnd out whether this upregulation oc-
curs at the level of transcription we carried out reporter gene as-
says with the human MDR1 promoter. A strong stimulation of
the promoter could be observed in EAPP overexpressing cells
(Fig. 2B). The MDR1 promoter exhibits a complex regulatory pat-
tern with numerous binding sites for transcriptional regulators
[9]. Fig. 2C shows a schematic drawing of the promoter region used
for the reporter assays.
3.2. Drugs can modulate the activation of the MDR1 promoter by EAPP
To address the question whether drugs known to be substrates
of PGP inﬂuence the activity of EAPP towards the MDR1 promoter
we overexpressed EAPP in T98G cells in the presence of colchicine,
methyl-methanesulfonate (MMS), etoposide, or nocodazole. Sub-
sequently we determined the levels of PGP by Western analysis
and the MDR1 promoter activity with reporter gene assays.
Fig. 2. EAPP induces the ABC transporter MDR1. (A) EAPP upregulates MDR1 protein levels. T98G cells were transfected with an HA-EAPP expression or a control vector,
harvested and analyzed by immunostaining with the corresponding antibodies. (B) EAPP increases MDR1 promoter activity. T98G cells were either transfected with an HA-
EAPP expression or a control vector and a MDR1-Luc vector harboring a truncated human MDR1-promoter in front of the luciferase gene. Reporter gene assays were carried
out with these cells. (C) Chart of the MDR1 promoter used for the reporter gene assays.
Fig. 3. The EAPP-dependent upregulation of MDR1 is inﬂuenced by certain drugs. (A) Western blot showing the differential increase of MDR1 protein levels upon EAPP
overexpression and drug treatment. T98G cells were transfected with the MDR1-Luc vector and a HA-EAPP expression or control vector and treated with the indicated drugs.
Levels of endogenous and HA-EAPP are shown. b-Actin was used as a loading control. (B) Quantiﬁcation of the signals of (A) using ImageQuant. The Actin signal was used for
normalization. All mock controls were set to 1 for better comparison of the real fold increase. (C) Luciferase assays showing the stimulation of the MDR1 promoter in the
presence of different drugs. T98G cells were treated as described in (A), harvested, and used for reporter assays.
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pression of EAPP at the protein level. Quantiﬁcation of the signals
(Fig. 3B) allowed the comparison with the effects seen in reportergene assays. The strongest effect was seen with nocodazole,
followed by etoposide. Reporter gene assays (Fig. 3C) conﬁrmed
this result in principle albeit with some variations. The overall
Fig. 4. The Y-Box is not required for regulation of the MDR1 promoter by EAPP and E2F1. (A) Reporter gene assays with the wild type MDR1-promoter and the MDR1-
promoter with a mutated Y-Box. T98G cells were transfected with either an HA-EAPP, an HA-E2F1, or a control vector additionally to a wild type or a mutated MDR1-Luc
vector carrying a mutation in the Y-Box of the promoter. Cells were harvested and a reporter gene assay was carried out. (B) Both mock controls of (A) were set to 1 for better
comparison of the real fold increase of the two MDR1-promoter constructs. (C) Corresponding Western blot showing the expression of HA-EAPP and HA-E2F1.
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corresponding increase of the protein.
3.3. E2F1 also stimulates the MDR1 promoter and this is further
enhanced by EAPP
Since EAPP interacts with the activating E2F proteins [12] it was
conceivable that E2F proteins are involved in the activation of
MDR1. Even though there are no canonical E2F binding sites within
the MDR1 promoter it is not implausible that E2F plays a role in its
regulation, considering the huge number of promoters where E2F is
present even without an E2F binding site [19,20]. Reporter gene
assays with both, the wt and the MDR1 promoter with a mutated
Y-Box [18] were carried out. The Y-Box (or inverted CCAAT-box) is
a ubiquitous element in eukaryotic housekeeping genes. It serves
as a binding site for transcription factors like YB-1 [21] or NF-Y
[22]. It turned out that E2F1 can also upregulate theMdr1 promoter.
Fig. 4A and B shows that ectopic E2F1 activates the Mdr1 promoter
stronger than EAPP despite lower expression levels (Fig. 4C).
Co-expression of both, E2F1 and EAPP stimulates promoter activityeven further. The mutation of the Y-Box reduced overall promoter
activity but did not affect the activation by EAPP and E2F1 (Fig. 4A
and B).
3.4. EAPP regulates the MDR1 promoter independently of E2F and is
not affected by pRb
EAPP is able to stimulate promoter activity in at least two differ-
ent manners. (1) It can associate with promoters via GC-boxes [14],
presumably by direct DNA binding [15], and (2) it activates tran-
scription via E2F factors [12]. To ﬁnd out whether the activation
of the MDR1 promoter by EAPP is E2F-dependent, we co-expressed
the retinoblastoma tumor suppressor protein (pRb), which binds
and inhibits the activating E2F factors in G1. In cycling cells, pRb
becomes phosphorylated by cyclin/cdk complexes resulting in
the release and activation of E2F [23,24]. To avoid the inactivation
of pRb we used a non-phosphorylatable and thus, constitutively
active mutant (pRbDcdk) [17]. Whereas the co-expression of
pRbDcdk considerably reduced the E2F-dependent activation of
the MDR1 promoter, it rather enhanced the EAPP-caused activation
Fig. 5. The regulation of the MDR1 promoter by EAPP seems to be independent of E2F1. (A) Reporter gene assay with the MDR1 promoter and different amounts of EAPP,
E2F1, and a constitutively active pRb. T98G cells were transfected with different combinations of either an HA-EAPP, an HA-E2F1, a pRB(Dcdk), or a control vector additionally
to the MDR1-Luc vector. Cells were harvested and reporter assays were carried out. (B) Corresponding Western analysis showing the expression levels of HA-EAPP, HA-E2F1,
and HA-pRB(Dcdk).
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stimulates the MDR1 promoter more efﬁciently in the absence of
active E2F.
4. Discussion
The expression level of MDR1 can be an important prognostic
factor in human cancers. High levels of MDR1 often correlate with
a poor response to chemotherapy and low complete remission
rates [25]. Elucidating the mechanisms that result in elevated
expression of multi drug resistance genes in general and MDR1
in particular and the development of drugs that interfere with their
activity has been a major goal of cancer biologists for many years
(reviewed in [26,27]) and is ongoing [28].
The expression of the human MDR1 gene, which is still incom-
pletely understood, seems to be inﬂuenced by a variety of pro-
moter-binding factors [9], but also by epigenetic events [10].
Very recently it has been shown that miRNAs can also be involved
in the regulation of this gene [29–31].
Our observations that both, E2F1 and EAPP can independently
stimulate the expression of MDR1, adds a new facet to the intricate
regulation of this gene. Increased E2F1 activity can result from the
inactivation of the retinoblastoma tumor suppressor [32,33], the
overexpression of c-myc [34,35], or DNA damage [36]. Since E2F1can induce apoptosis via p53-dependent [37,38] and – independent
pathways [39,40] compensatory mechanisms would be required to
prevent apoptosis in a transforming cell. One of these mechanisms
could be the concomitant induction of EAPP resulting in elevated
p21 levels [14]. Although the prime activity of p21 is the induction
of cell cycle arrest or senescence it also exhibits strong anti-apopto-
tic properties [41] and acts as a negative regulator of p53 [42]. If
pRb is already inactive, such a cell might proliferate unabated and
become the nucleus of a tumor. The ability of EAPP to stimulate
E2F-dependent transcription could be an additional advantage for
a transforming cell with elevated levels of both kinds of proteins.
The concurrent upregulation of MDR1/PGP might be only a side
effect in the early stages of cancerogenesis but might contribute
to the survival of tumor cells during chemotherapy and worsen
the prognosis for the patient.
The stimulation of the MDR1 promoter by EAPP was more
pronounced in cells treated with etoposide or nocodazole than in
untreated or MMS- and colchicine-treated cells (Fig. 3). The mech-
anism for this is unclear but in the case of etoposide it might be
mediated by the protein kinase CK2 which relocalizes upon etopo-
side treatment [43] and is also strongly phosphorylating EAPP
(Rotheneder, unpublished).
How could EAPP stimulate PGP expression? Although E2F1 also
enhances MDR1 promoter activity (Fig. 4), this can be repressed by
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independent mechanism. Interestingly, the repression of E2F by
pRb(Dcdk) seemed to result in stronger activation by EAPP
(Fig. 5A). This could mean that there is a competition between
E2F1 and EAPP. The MDR1 promoter comprises GC boxes serving
as binding sites for Sp1 like proteins which have been shown to
stimulate MDR1 expression [44]. We and others have found earlier
that E2F1 interacts with Sp1 and this seems to be required for the
activity of certain promoters [45,46]. On the other hand, EAPP can
compete with Sp1 for GC boxes [14,15]. Taken together this could
explain our observations. According to this model E2F1 stimulates
the MDR1 promoter by interacting with Sp1, which could also sta-
bilize DNA binding of Sp1. pRb might interfere with this interaction
thereby giving way for the displacement of Sp1 by EAPP.
A better understanding of the mechanisms resulting in multi-
drug resistance of which EAPP and E2F1 seem to be part of might
help to prevent its development or allow its suppression and there-
by increase the efﬁcacy of chemotherapy.Acknowledgements
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